exatecan

Business news, market intelligence, and global industry analysis.

The Latest

Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts

Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

January 26, 2026